Inhibrx (NASDAQ:INBX – Get Free Report) is anticipated to issue its quarterly earnings data before the market opens on Thursday, February 27th. Analysts expect the company to announce earnings of ($2.88) per share for the quarter.
Inhibrx Stock Down 0.6 %
INBX opened at $12.49 on Tuesday. The business’s 50 day moving average is $13.78 and its 200-day moving average is $14.59. Inhibrx has a twelve month low of $10.80 and a twelve month high of $18.95.
Analyst Ratings Changes
Separately, JMP Securities reaffirmed a “market perform” rating on shares of Inhibrx in a report on Wednesday, January 22nd.
About Inhibrx
Inhibrx, Inc, a clinical-stage biopharmaceutical company, develops a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidate includes INBRX-101, an alpha-1 antitrypsin (AAT)-Fc fusion protein therapeutic candidate, which is in Phase 1 clinical trials for use in the treatment of patients with AAT deficiency.
Read More
- Five stocks we like better than Inhibrx
- 10 Best Airline Stocks to Buy
- The Behemoth BlackRock’s Next Trillion Comes From Private Assets
- Russell 2000 Index, How Investors Use it For Profitable Trading
- Rivian’s Rough Patch: Is the Dip a Doorway to Long-Term Gains?
- Compound Interest and Why It Matters When Investing
- Institutions Signal Opportunty to Buy High-Yield Kraft-Heinz
Receive News & Ratings for Inhibrx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inhibrx and related companies with MarketBeat.com's FREE daily email newsletter.
